ClinicalTrials.gg
CompletedNCT04772534Updated May 30, 2025Results posted

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

A Phase 3 interventional study of 9vHPV vaccine in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in Japan. Open to participants aged 9 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
9 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
21st of 31
314 · median 700
Started
2021
with 3 others
Phase 3
16 of 31
2 open now
Registered
16th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 21st largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 16th registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

The primary objective of this study is the estimation of the human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58 seroconversion at 1 month post last dose (Month 7) following 3 doses and 2 doses of the 9-valent human papillomavirus (9vHPV) vaccine. No hypothesis will be tested since this study is an estimation-only study.

03

Conditions studied

  • Papillomavirus Infections
04

Who can participate

Ages eligible
9 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is Japanese male or female.
  • Is aged at the time of providing the documented (inclusive): (3-dose boy arm) male from 9 years to 15 years old, (2-dose boy arm) male from 9 years to 14 years old, or (2-dose girl arm) female from 9 years to 14 years old.
  • Has a legally acceptable representative who can read, understand and complete the vaccination report card (VRC).
  • Has not yet had coitarche and does not plan on becoming sexually active during the Day 1 through Month 7.

Exclusion criteria

Exclusion Criteria:

  • Has a fever (defined as oral temperature ≥37.5°C) within the 24-hour period prior to the Day 1 visit.
  • Has a history of severe allergic reaction that required medical intervention.
  • Is allergic to any vaccine component, including aluminum, yeast, or Benzonase™.
  • Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • Is currently or has been diagnosed as having a congenital or acquired immunodeficiency, (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other auto immune condition.
  • Has a history of splenectomy.
  • Has a history of genital warts or positive test for human papillomavirus (HPV).
  • Is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within 12 months) of drug or alcohol abuse or dependence at the discretion of the investigator. .
  • Has received within 12 months prior to enrollment, is receiving, or plans to receive during Day 1 through Month 7 of the study, any study-prohibited concomitant immunosuppressive therapy .
  • Has received within the 3 months prior to the Day 1 vaccination, is receiving, or plans to receive during Day 1 through Month 7 of the study, any immune globulin product or blood-derived product other than intravenous gamma globulin (IVIG).
  • Has received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or receipt of within 28 days prior to Day 1 vaccination.
  • Has previously received a marketed HPV vaccine or has participated in a clinical trial for any HPV vaccine (receiving either active agent or placebo).
  • Is concurrently enrolled in other clinical studies of agents.
  • Is unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    3-dose in 9 to 15 year old boys

    9 to 15 year old boys will receive a 3-dose regimen of 9vHPV vaccine (Day 1, Month 2 and Month 6).

    Biological: 9vHPV vaccine

  • Experimental
    2-dose in 9 to 14 year old boys

    9 to 14 year old boys receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).

    Biological: 9vHPV vaccine

  • Experimental
    2-dose in 9 to 14 year old girls

    9 to 14 year old girls receive a 2-dose regimen of 9vHPV vaccine (Day 1 and Month 6).

    Biological: 9vHPV vaccine

Interventions

  • Biological9vHPV vaccine

    9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

    Also known as: V503, SILGARD®9, GARDASIL™9

06

What researchers measure

Primary outcomes

  1. Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    The percentage of seropositive participants is reported. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA). Seroconversion was defined as changing serostatus from seronegative at Day 1 to seropositive at 4 weeks post last vaccination.

    Time frame: 1 month after final dose (Month 7)

  2. Number of Participants With at Least 1 Injection-site Adverse Event (AE)

    The number of participants with injection-site AEs (erythema/redness, pain and swelling) is reported. An AE any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 5 days after each vaccination (up to ~6 months)

  3. Number of Participants With at Least 1 Systemic Adverse Event

    The number of participants with a systemic AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 15 days after each vaccination (up to ~6.5 months)

  4. Number of Participants With at Least 1 Serious Adverse Event (SAE)

    The number of participants with an SAE is reported. An SAE is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention.

    Time frame: Up to ~Month 30

Secondary outcomes

  1. Geometric Mean Titers (GMTs) for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    The GMT for each HPV serotype is presented. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA).

    Time frame: 1 month after final dose (Month 7)

07

Results

Posted May 30, 2025

Participant flow

Participant flow — Overall Study
Milestone3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
Started105104105
Completed101104104
Not completed401
Withdrew: Physician decision100
Withdrew: Withdrawal by subject301

Outcome measures

PrimarySeroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

The percentage of seropositive participants is reported. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA). Seroconversion was defined as changing serostatus from seronegative at Day 1 to seropositive at 4 weeks post last vaccination.

Time frame:
1 month after final dose (Month 7)
Reported as:
Number · Percentage of Participants
Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Percentage of Participants3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
Anti-HPV 6100.0 (96.0 to 100.0)100.0 (96.0 to 100.0)100.0 (96.1 to 100.0)
Anti-HPV 11100.0 (96.0 to 100.0)100.0 (96.0 to 100.0)100.0 (96.1 to 100.0)
Anti-HPV 16100.0 (96.3 to 100.0)100.0 (96.3 to 100.0)100.0 (96.3 to 100.0)
Anti-HPV 18100.0 (96.2 to 100.0)100.0 (96.1 to 100.0)100.0 (95.7 to 100.0)
Anti-HPV 31100.0 (96.0 to 100.0)100.0 (96.1 to 100.0)100.0 (96.0 to 100.0)
Anti-HPV 33100.0 (95.8 to 100.0)100.0 (96.0 to 100.0)100.0 (96.2 to 100.0)
Anti-HPV 45100.0 (96.2 to 100.0)100.0 (96.2 to 100.0)100.0 (96.3 to 100.0)
Anti-HPV 52100.0 (96.3 to 100.0)100.0 (96.2 to 100.0)100.0 (96.3 to 100.0)
Anti-HPV 58100.0 (96.4 to 100.0)100.0 (96.4 to 100.0)100.0 (96.3 to 100.0)
PrimaryNumber of Participants With at Least 1 Injection-site Adverse Event (AE)

The number of participants with injection-site AEs (erythema/redness, pain and swelling) is reported. An AE any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to 5 days after each vaccination (up to ~6 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Injection-site Adverse Event (AE)
Participants3-Dose Regimen: 9 to 15 Year Old Boys2-dose in 9 to 14 Year Old Boys2-dose in 9 to 14 Year Old Girls
Number of Participants With at Least 1 Injection-site Adverse Event (AE)878592
PrimaryNumber of Participants With at Least 1 Systemic Adverse Event

The number of participants with a systemic AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to 15 days after each vaccination (up to ~6.5 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Systemic Adverse Event
Participants3-Dose Regimen: 9 to 15 Year Old Boys2-dose in 9 to 14 Year Old Boys2-dose in 9 to 14 Year Old Girls
Number of Participants With at Least 1 Systemic Adverse Event554133
PrimaryNumber of Participants With at Least 1 Serious Adverse Event (SAE)

The number of participants with an SAE is reported. An SAE is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention.

Time frame:
Up to ~Month 30
Reported as:
Count of participants · Participants
Number of Participants With at Least 1 Serious Adverse Event (SAE)
Participants3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
Number of Participants With at Least 1 Serious Adverse Event (SAE)023
SecondaryGeometric Mean Titers (GMTs) for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

The GMT for each HPV serotype is presented. Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined using competitive Luminex Immunoassay (cLIA).

Time frame:
1 month after final dose (Month 7)
Reported as:
Geometric mean · GMT (mMU/mL)
Geometric Mean Titers (GMTs) for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
GMT (mMU/mL)3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
Anti-HPV 61759.8 (1481.2 to 2090.8)2417.0 (2057.3 to 2839.6)2343.2 (2036.1 to 2695.5)
Anti-HPV 111341.8 (1136.1 to 1584.9)1510.1 (1310.3 to 1740.4)1508.5 (1340.8 to 1697.0)
Anti-HPV 167020.8 (5955.3 to 8277.1)9808.5 (8437.7 to 11402.0)9800.0 (8440.1 to 11379.1)
Anti-HPV 182629.6 (2154.7 to 3209.1)2464.6 (2095.6 to 2898.5)2999.8 (2509.3 to 3586.3)
Anti-HPV 312095.0 (1717.2 to 2555.9)1908.5 (1619.3 to 2249.4)1838.7 (1571.8 to 2151.0)
Anti-HPV 33894.9 (753.1 to 1063.4)1272.1 (1085.2 to 1491.2)1283.1 (1132.4 to 1453.8)
Anti-HPV 45848.9 (701.1 to 1027.8)508.4 (431.7 to 598.8)599.6 (520.6 to 690.4)
Anti-HPV 52925.3 (774.9 to 1105.0)587.4 (503.3 to 685.5)582.7 (517.3 to 656.4)
Anti-HPV 581401.7 (1177.4 to 1668.8)1350.6 (1155.1 to 1579.1)1379.8 (1216.4 to 1565.1)

Adverse events

Collected over Up to ~Month 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3-Dose Regimen: 9 to 15 Year Old Boys0/103 (0%)0/103 (0%)18/103 (17.5%)
2-dose Regimen: 9 to 14 Year Old Boys0/104 (0%)2/104 (1.9%)12/104 (11.5%)
2-dose Regimen: 9 to 14 Year Old Girls0/104 (0%)3/104 (2.9%)8/104 (7.7%)
Most frequent serious events
Most frequent serious events
Event3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
Anaphylactic reactionImmune system disorders0/1031/1041/104
Pyelonephritis acuteInfections and infestations0/1030/1041/104
Tympanic membrane perforationEar and labyrinth disorders0/1031/1040/104
StrabismusEye disorders0/1030/1041/104
Most frequent other events
Most frequent other events
Event3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old Girls
PyrexiaGeneral disorders18/10312/1048/104
HeadacheNervous system disorders10/1039/1046/104
NasopharyngitisInfections and infestations6/1033/1044/104

Baseline characteristics

Age, Continuous
Age, Continuous(Years)3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old GirlsTotal
Mean11.8 ± 2.011.5 ± 1.711.4 ± 1.611.6 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old GirlsTotal
Female00105105
Male1051040209
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old GirlsTotal
Hispanic or Latino0000
Not Hispanic or Latino105104105314
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)3-Dose Regimen: 9 to 15 Year Old Boys2-dose Regimen: 9 to 14 Year Old Boys2-dose Regimen: 9 to 14 Year Old GirlsTotal
American Indian or Alaska Native0000
Asian105104105314
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

12 sites
  • Sotobo Children's Clinic ( Site 6616)
    Isumi-shi, Chiba 299-4503, Japan
  • Ohigesenseino Kodomo Clinic ( Site 6607)
    Sapporo, Hokkaido 062-0907, Japan
  • Motomachi Pediatric Clinic ( Site 6606)
    Sapporo, Hokkaido 065-0024, Japan
  • Medical Corporation Bunmeikai Okuda E.N.T ( Site 6611)
    Sakai, Osaka 593-8322, Japan
  • Fukui General Hospital ( Site 6614)
    Fukui, 910-8561, Japan
  • Nomura Clinic Namba ( Site 6608)
    Osaka, 542-0076, Japan
  • Medical Corporation Kanyukai Kikumori Otolaryngology Clinic ( Site 6612)
    Osaka, 554-0014, Japan
  • Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 6603)
    Tokyo, 101-0041, Japan
  • Okawa Children & Family Clinic ( Site 6610)
    Tokyo, 146-0095, Japan
  • Shinjuku Higashiguchi Clinic ( Site 6602)
    Tokyo, 160-0022, Japan
  • Hayashi Clinic ( Site 6615)
    Tokyo, 167-0051, Japan
  • Ogikuboekimae Clinic ( Site 6601)
    Tokyo, 167-0051, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Apr 2024, 34 months.

Results were first posted in May 2025, 1 year 1 month after primary completion.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 34 months is above that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2021
First posted
Feb 26, 2021
StartActual
May 17, 2021
Primary completionActual
Apr 6, 2024
CompletionActual
Apr 6, 2024
Results first posted
May 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04772534
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
May 17, 2021
Primary completion
Apr 6, 2024
Completion
Apr 6, 2024
Results posted
May 30, 2025
Last update
May 30, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion